Pédiatrique divers

  • Accueil
  • Pédiatrique divers
  • ABLE 2.0 /? PTCTC GVH 1901

TITRE (EN) Biomarker Verification in Pediatric Chronic Graft-Versus-Host Disease: Applied Biomarkers to Minimize Long Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) / Pediatric Transplantation & Cellular Therapy Consortium (PTCTC)
PROTOCOLE ID ABLE 2.0 /? PTCTC GVH 1901
CLINICAL TRIAL.gov ID NCT04372524
TYPE(S) DE CANCER Pédiatrique divers
PHASE Autres
TYPE D'ÉTUDE
INSTITUTION CENTRE HOSPITALIER UNIVERSITAIRE SAINTE-JUSTINE
3175 Chemin de la Côte Sainte-Catherine
(514) 345-4931
VILLE Montréal
INVESTIGATEUR(RICE) PRINCIPAL(E) Henrique Bittencourt
COORDONATEUR(RICE) David Godin
514-345-4931 poste 3455
STATUT  Actif en recrutement
CRITÈRES D'ÉLIGIBILITÉ (EN)
  • Any indication for allogeneic hematopoietic stem cell transplant (malignant or non-malignant)
  • Age 0 - 24.99 years at the time of transplant (on day 0)
  • Any conditioning regimen (including myeloablative or reduced-toxicity/reduced-intensity)
  • Any graft source (bone marrow, peripheral blood, cord blood)
  • Any graft-versus-host disease prophylaxis strategy, including serotherapy such as ATG or alemtuzumab
  • Haploidentical transplants, including post-transplant cyclophosphamide and alpha-beta TCR depletion, are allowed
CRITÈRES D'EXCLUSION (EN)
  • Second or greater allogeneic transplant
  • Weight 7 kg or less
  • Pure CD34+ selected haploidentical stem cell transplant (not including CD34 enrichment used in alpha-beta TCR depleted haploidentical transplants, which is allowed)
  • Inability of a center to follow a patient for the development of late-acute and chronic GVHD until 1-year post-transplant (referral sites who transplant patients from outside institutions should not enroll participants if sending back to the referring site early, such that long-term follow up, blood, and data collection cannot be assured).